Corbus Pharmaceuticals (CRBP) Expected to Announce Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($1.30) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.03. On average, analysts expect Corbus Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Corbus Pharmaceuticals Stock Up 5.4%

CRBP stock traded up $0.48 during midday trading on Tuesday, reaching $9.40. The stock had a trading volume of 103,138 shares, compared to its average volume of 327,456. The business has a fifty day simple moving average of $8.57 and a two-hundred day simple moving average of $9.01. The firm has a market cap of $174.18 million, a price-to-earnings ratio of -1.62 and a beta of 2.59. Corbus Pharmaceuticals has a twelve month low of $7.12 and a twelve month high of $20.56.

Insiders Place Their Bets

In other Corbus Pharmaceuticals news, insider Nishant C. Saxena acquired 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $7.58 per share, with a total value of $68,220.00. Following the purchase, the insider owned 75,300 shares of the company’s stock, valued at $570,774. This represents a 13.57% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Kenneth Jenkins sold 4,800 shares of Corbus Pharmaceuticals stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $7.91, for a total value of $37,968.00. Following the transaction, the director owned 3,833 shares in the company, valued at approximately $30,319.03. This represents a 55.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 9,238 shares of company stock valued at $73,073. 3.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of hedge funds have recently modified their holdings of CRBP. Engineers Gate Manager LP bought a new stake in Corbus Pharmaceuticals during the 4th quarter worth approximately $140,000. Caption Management LLC lifted its stake in Corbus Pharmaceuticals by 170.1% in the fourth quarter. Caption Management LLC now owns 56,066 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 136,066 shares in the last quarter. Trexquant Investment LP boosted its holdings in shares of Corbus Pharmaceuticals by 124.2% in the fourth quarter. Trexquant Investment LP now owns 27,275 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 15,110 shares during the period. Laurion Capital Management LP acquired a new position in shares of Corbus Pharmaceuticals in the fourth quarter valued at approximately $151,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Corbus Pharmaceuticals during the fourth quarter worth $244,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Analyst Upgrades and Downgrades

CRBP has been the topic of a number of research reports. Guggenheim restated a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. Wall Street Zen raised shares of Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Jefferies Financial Group cut their price objective on shares of Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Mizuho cut their price objective on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating on the stock in a report on Tuesday, June 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Corbus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $42.25.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.